文献速递血管炎系统性红斑狼疮

呼吁在ANCA相关性血管炎和狼疮肾炎中采取行动:SGLT-2抑制剂的希望与挑战

Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors.
PubMed 文献 · Ann Rheum Dis · 2021-11-29

本文呼吁在ANCA相关性血管炎(AAV)和狼疮肾炎(LN)患者中研究SGLT-2抑制剂(SGLT-2i)的肾脏和心血管保护作用。SGLT-2i在大型心血管结局试验中显示出显著心肾保护作用,可减少慢性肾脏病(CKD)进展包括白蛋白尿,并在伴或不伴2型糖尿病的心力衰竭患者中在血管紧张素阻断剂基础上改善结局。由于近期大型肾脏结局试验均排除自身免疫病患者,作者主张研究这类疾病修饰疗法在AAV和LN患者中的应用。

要点

  • SGLT-2i在大型心血管结局试验中显示出显著心肾保护作用,可减少CKD进展包括白蛋白尿。
  • SGLT-2i在伴或不伴2型糖尿病的心力衰竭患者中在血管紧张素阻断剂基础上改善结局。
  • 近期大型肾脏结局试验均排除自身免疫病患者,作者主张在AAV和LN患者中研究SGLT-2i。

核心结论

  • 作者主张在ANCA相关性血管炎和狼疮肾炎患者中研究SGLT-2抑制剂这类疾病修饰疗法对肾脏和心血管健康的作用。
  • CKD仍是ANCA相关性血管炎和狼疮肾炎患者不良预后的最强预测因素之一,也是超额死亡的独立危险因素。

研究设计与样本

  • 本文为呼吁性文章,基于对SGLT-2抑制剂大型心血管结局试验及机制研究的综述提出研究倡议。

主要发现

  • SGLT-2i在大型心血管结局试验中显示出显著心肾保护作用,可减少慢性肾脏病进展包括白蛋白尿。
  • SGLT-2i在伴或不伴2型糖尿病的心力衰竭患者中在血管紧张素阻断剂基础上改善结局,并改善心肾风险患者的死亡率。
  • SGLT-2i的临床获益机制并非源于其降糖特性,而是涉及减少肾小球高滤过和肾小管保护。
  • SGLT-2i副作用特征有利,尤其在非糖尿病患者中还可降低急性肾损伤风险。
  • 近期大型肾脏结局试验均排除自身免疫病患者。

临床怎么用

  • 作者主张研究SGLT-2抑制剂在ANCA相关性血管炎和狼疮肾炎患者中对肾脏和心血管健康的作用。

局限性

  • SGLT-2i产生这些临床结局的详细分子机制尚未完全阐明。
  • 近期大型肾脏结局试验均排除自身免疫病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium-glucose cotransporter- 2 inhibitors (SGLT- 2i) have recently been demonstrated to exert profound cardio- and nephroprotection in large cardiovascular outcome trials. They reduce progression of chronic kidney disease (CKD) including albuminuria and improve outcomes in heart failure patients with and without type 2 diabetes on top of angiotensin-blocking agents. These benefits translate into improved mortality in cardiorenal risk patients. While the detailed molecular mechanisms underlying these surprising clinical outcomes are not fully understood, their antidiabetic properties are not causative. Rather reduction of glomerular hyperfiltration and tubuloprotection are involved as root cause mechanisms of their clinical effects. Finally, their side effect profile is advantageous especially in non-diabetic patients also reducing the risk of acute kidney injury. Among the independent risk factors for excess mortality, CKD is still one of the strongest predictors of a poor prognosis in patients with both ANCA- associated vasculitis (AAV) and lupus nephritis (LN). Since patients with autoimmune disease were excluded from all recent large renal outcome trials with SGLT-2i and given their strong nephroprotective potential, we herein advocate to study this unique class of disease-modifying therapies when it comes to kidney and cardiovascular health in patients with AAV and LN.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Säemann M, Kronbichler A. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. Ann Rheum Dis. 2021. PMID: 34844933. doi:10.1136/annrheumdis-2021-221474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。